徳島大学 / 教育研究者総覧 --- 三橋惇志

個人のホームページ

https://orcid.org/0000-0002-0235-6399 (ORCID)

専門分野

研究テーマ

著書・論文

学術論文(審査論文):

1.	Yohei Yabuki, Atsushi Mitsuhashi, Hirokazu Ogino, Aito Yoshida, Thi Na Nguyen, Hiroto Yoneda, Ryohiko Ozaki, Yuki Tsukazaki, Yutaka Morita, Hiroshi Nokihara, Seidai Satou, Tsutomu Shinohara, Masaki Hanibuchi and Yasuhiko Nishioka : Hypoxia-inducible factor-targeting therapy augmented the sensitivity to programmed death ligand-1 blockade by enhancing interferon-γ-induced chemokines in tumor cells, International Journal of Cancer, 156, 9, 1814-1825, 2024. (要約) Immune checkpoint inhibitors (ICIs) targeting programmed death ligand-1 (PD-L1) provide clinical benefits for various advanced malignancies. However, the predictive factors that determine sensitivity to ICIs have not been fully elucidated. We focused on tumor-derived CXCL10/11 as a pivotal factor that determines the response to PD-L1 blockade by regulating T cell accumulation and tumor angiogenesis. We previously reported that CXCL10/11 was upregulated by interferon (IFN)-γ in ICI-sensitive tumor cells but not in ICI-resistant cells, including mouse Lewis lung carcinoma (LLC). In the present study, gene silencing of tumor-derived CXCL10/11 induced resistance to PD-L1 blockade in AB1-HA mesothelioma cell-bearing mice. To identify the mechanisms underlying ICI resistance, we performed a microarray analysis to compare the IFN-γ-inducible genes between ICI-sensitive AB1-HA and ICI-resistant LLC in vitro. A pathway analysis based on microarray data indicated that hypoxia-inducible factor (HIF) 1A is the key signal that inhibits CXCL10/11 expression. We revealed that the HIF1A inhibitors echinomycin (EC) and YC-1 upregulated CXCL10/11 genes induced by IFN-γ in tumor cells in vitro. In addition, combination therapy with PD-L1 blockade and EC demonstrated synergistic antitumor effects in LLC-bearing mice. Combination therapy enhanced tumor infiltration of CD8 T cells and suppressed tumor angiogenesis. The present study suggests that HIF1A signaling in tumor cells dominates ICI resistance via the downregulation of tumor-derived CXCL10/11. (キーワード) angiogenesis / CXCL10/11 / HIF1A / immune checkpoint inhibitor / interferon-γ (徳島大学機関リポジトリ) ● Metadata: 2013332 (出版サイトへのリンク) ● Publication site (DOI): 10.1002/ijc.35301 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39686841 ● Summary page in Scopus @ Elsevier: 2-s2.0-85212305972 (徳島大学機関リポジトリ: 2013332, DOI: 10.1002/ijc.35301, PubMed: 39686841, Elsevier: Scopus)
2.	Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yuko Toyoda, Yugo Matsumura, Seiya Ichihara, Takeshi Imakura, Rikako Matsumoto, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Kayoko Hase, Eiji Takeuchi, Takashi Haku and Yasuhiko Nishioka : Granulocyte colony-stimulating factor has the potential to attenuate the therapeutic efficacy of chemo-immunotherapy for extensive-stage small-cell lung cancer, International Journal of Clinical Oncology, 29, 10, 1451-1460, 2024. (要約) Granulocyte colony-stimulating factor (G-CSF) has the potential to attenuate the anti-tumor immune responses of T-cells by increasing immune suppressive neutrophils and myeloid-derived suppressor cells. However, the clinical impact of G-CSF on the efficacy of immunotherapy remains unknown. This multi-center retrospective analysis evaluated the impact of G-CSF in patients with extensive-stage small-cell lung cancer (ES-SCLC) treated with chemo-immunotherapy. We analyzed 65 patients with ES-SCLC who completed four cycles of induction chemo-immunotherapy and evaluated the effects of G-CSF on progression-free survival (PFS), overall survival (OS), and a durable response to immunotherapy (defined as PFS 12 months). Fifty patients (76.9%) received 1 dose of G-CSF. The PFS of the patients with G-CSF was poorer than that of the patients without G-CSF (median PFS 8.3 vs. 4.9 months, p = 0.009). The OS of the patients with G-CSF tended to be shorter, but not statistically significant, than that of the patients without G-CSF (median OS 24.3 vs. 16.4 months, p = 0.137). In the multivariate analysis, G-CSF administration was associated with poorer PFS (hazard ratio 2.78, 95% CI 1.36-5.69, p = 0.005) and was identified as a determinant of a durable response (odds ratio 0.18, 95% CI 0.04-0.80, p = 0.024). These results were consistent with other definitions of G-CSF administration (administration of 1 dose of pegfilgrastim, or either 5 doses of filgrastim or 1 dose of pegfilgrastim). G-CSF has the potential to attenuate the efficacy of immunotherapy; therefore, the indication for G-CSF during chemo-immunotherapy should be carefully considered for ES-SCLC. (キーワード) Chemo-immunotherapy / Extensive-stage small-cell lung cancer / Granulocyte colony-stimulating factor (出版サイトへのリンク) ● Publication site (DOI): 10.1007/s10147-024-02586-0 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39009900 ● Summary page in Scopus @ Elsevier: 2-s2.0-85198503607 (DOI: 10.1007/s10147-024-02586-0, PubMed: 39009900, Elsevier: Scopus)
3.	Hiroyuki Kozai, Hirokazu Ogino, Atsushi Mitsuhashi, Thi Na Nguyen, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi, Tsutomu Shinohara, Hiroshi Nokihara and Yasuhiko Nishioka : Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies., Thoracic Cancer, 15, 5, 369-378, 2024. (要約) 5-FU induced cell surface expression of CRT and ATP secretion most efficiently among the several chemotherapeutic agents. This effect was enhanced when it was combined with platinum. In the antitumor vaccination assay in vivo, we found that vaccination with dying-AB1-HA (a murine malignant mesothelioma cell line) cells treated with 5-FU, but neither PEM nor PTX, reduced the tumor growth of living-AB1-HA cells inoculated 1 week after vaccination by recruiting CD3 (キーワード) Humans / Animals / Mice / Carcinoma, Non-Small-Cell Lung / Immune Checkpoint Inhibitors / CD8-Positive T-Lymphocytes / Platinum / Immunogenic Cell Death / Lung Neoplasms / Pemetrexed / Antimetabolites / Cell Line, Tumor / Taxoids / Fluorouracil / Adenosine Triphosphate / Tumor Microenvironment (徳島大学機関リポジトリ) ● Metadata: 2012077 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/1759-7714.15200 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38146645 ● Search Scopus @ Elsevier (PMID): 38146645 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15200 (徳島大学機関リポジトリ: 2012077, DOI: 10.1111/1759-7714.15200, PubMed: 38146645)
4.	Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Thi Na Nguyen, Hiroshi Nokihara, Seidai Satou, Tsutomu Shinohara, Masaki Hanibuchi, Shinji Abe, K Mika Kaneko, Yukinari Kato and Yasuhiko Nishioka : Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells., Cancer Science, 115, 2, 357-368, 2024. (要約) -f and CTLA-4 blockade in vivo. These findings indicated the essential role of NK cells in novel combination immunotherapy targeting PDPN and shed light on the therapeutic strategy in advanced MPM. (キーワード) Rats / Mice / Animals / Cricetinae / Mesothelioma, Malignant / Antibodies, Monoclonal / CTLA-4 Antigen / Membrane Glycoproteins / Mesothelioma / Killer Cells, Natural / Cricetulus / CHO Cells (徳島大学機関リポジトリ) ● Metadata: 2011937 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/cas.16046 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38148492 ● Search Scopus @ Elsevier (PMID): 38148492 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.16046 (徳島大学機関リポジトリ: 2011937, DOI: 10.1111/cas.16046, PubMed: 38148492)
5.	Kenya Miyamoto, Hirokazu Ogino, Takumi Kakimoto, Yugo Matsumura, Keiko Haji, Atsushi Mitsuhashi, Yutaka Morita, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi, Yoshimi Bando, Hiroshi Nokihara and Yasuhiko Nishioka : Transformation of epidermal growth factor receptor mutated lung adenocarcinoma to small-cell carcinoma long after the cessation of tyrosine kinase inhibitor treatment: A case series and literature review, Respiratory Medicine Case Reports, 51, 102076, 2024. (キーワード) Acquired resistance / Epidermal growth factor receptor / Non-small-cell lung cancer / Small-cell lung cancer transformation / Tyrosine kinase inhibitors (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.rmcr.2024.102076 (文献検索サイトへのリンク) ● Summary page in Scopus @ Elsevier: 2-s2.0-85196709618 (DOI: 10.1016/j.rmcr.2024.102076, Elsevier: Scopus)
6.	Yohei Yabuki, Masaki Hanibuchi, Eiji Takeuchi, Takashi Haku, Takanori Kanematsu, Naoki Nishimura, Yuko Toyoda, Atsushi Mitsuhashi, Kenji Otsuka, Seidai Satou, Hisatsugu Goto, Hiroto Yoneda, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer., Thoracic Cancer, 14, 32, 3232-3239, 2023. (要約) The median age at initiating chemotherapy was 80 years old. Almost all patients (92.6%) had adenocarcinoma histology. The median number of cycles administered was 6, and the objective response rate was 40.7%. The median progression-free survival, overall survival and 1-year survival were 8.8 months, 27.2 months and 79%, respectively. The treatment was well-tolerated, and no treatment-related death was observed. (キーワード) Humans / Aged / Aged, 80 and over / Carcinoma, Non-Small-Cell Lung / Pemetrexed / Bevacizumab / Lung Neoplasms / Treatment Outcome / Antineoplastic Combined Chemotherapy Protocols (徳島大学機関リポジトリ) ● Metadata: 2012168 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/1759-7714.15115 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37718463 ● Search Scopus @ Elsevier (PMID): 37718463 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.15115 (徳島大学機関リポジトリ: 2012168, DOI: 10.1111/1759-7714.15115, PubMed: 37718463)
7.	Hiroki Takahashi, Hirokazu Ogino, Hiroki Bando, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroto Yoneda, Seidai Satou, Masaki Hanibuchi and Yasuhiko Nishioka : FoundationOne CDx detected an uncovered variant of epidermal growth factor receptor exon 19 deletion by Oncomine Dx target test in a patient with lung adenocarcinoma., Respiratory Medicine Case Reports, 45, 101893, 2023. (徳島大学機関リポジトリ) ● Metadata: 2012094 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.rmcr.2023.101893 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37485237 ● Search Scopus @ Elsevier (PMID): 37485237 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2023.101893 (徳島大学機関リポジトリ: 2012094, DOI: 10.1016/j.rmcr.2023.101893, PubMed: 37485237)
8.	Atsushi Mitsuhashi, Kazuya Koyama, Hirokazu Ogino, Tania Afroj, Thi Na Nguyen, Hiroto Yoneda, Kenji Otsuka, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara, Masaki Hanibuchi, Hiromitsu Takizawa, Tsutomu Shinohara and Yasuhiko Nishioka : Identification of fibrocyte cluster in tumors reveals the role in antitumor immunity by PD-L1 blockade., Cell Reports, 42, 3, 112162, 2023. (要約) fibrocytes is enhanced by anti-PD-L1 antibody. Peritumoral implantation of fibrocytes enhances the antitumor effect of PD-L1 blockade in vivo; CD86 (キーワード) Humans / 血管内皮増殖因子 (vascular endothelial growth factor) / Neoplasms / B7-H1 Antigen / 免疫療法 (immunotherapy) / Tumor Microenvironment (徳島大学機関リポジトリ) ● Metadata: 2011623 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.celrep.2023.112162 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36870329 ● Search Scopus @ Elsevier (PMID): 36870329 ● Search Scopus @ Elsevier (DOI): 10.1016/j.celrep.2023.112162 (徳島大学機関リポジトリ: 2011623, DOI: 10.1016/j.celrep.2023.112162, PubMed: 36870329)
9.	Masaki Hanibuchi, Atsushi Mitsuhashi, Atsuro Saijo, Tatsuya Kajimoto, Seidai Satou, Tetsuya Kitagawa and Yasuhiko Nishioka : A case of atopic cough with aphonia showed a prominent response to a histamine H1 receptor antagonist., The Journal of Medical Investigation : JMI, 70, 1.2, 281-284, 2023. (要約) -RA, a diagnosis of AC was made. To the best of our knowledge, this is the first report of an AC patient who presented severe cough with aphonia. J. Med. Invest. 70 : 281-284, February, 2023. (キーワード) 成人 (adult) / 女性 (female) / Humans / Aphonia / Cough / Histamine H1 Antagonists (出版サイトへのリンク) ● Publication site (DOI): 10.2152/jmi.70.281 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164735 ● Search Scopus @ Elsevier (PMID): 37164735 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.281 (DOI: 10.2152/jmi.70.281, PubMed: 37164735)
10.	T Na Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Tania Afroj, Seidai Satou, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : S-1 eliminates MDSCs and enhances the efficacy of PD-1 blockade via regulation of tumor-derived Bv8 and S100A8 in thoracic tumor., Cancer Science, 114, 2, 384-398, 2023. (要約) Myeloid-derived suppressor cells (MDSCs) have been known to play a pivotal role in the induction of immune tolerance, which limits the benefits of immune checkpoint inhibitors (ICIs). Recent studies revealed that several chemotherapeutic agents decreased tumor-infiltrating MDSCs. Therefore, combination therapy with cytotoxic chemotherapeutic agents and ICIs was approved for first-line treatment for lung cancer. However, the impact of chemotherapeutic agents on MDSCs and an optimal partner of ICIs has not been fully investigated in thoracic tumors, including lung cancer and malignant pleural mesothelioma. In the present study, we found that treatment with 5-FU and its oral formulation, S-1, suppressed tumor progression and inhibited the accumulation of MDSCs in thoracic tumor-bearing mice. Tumor-infiltrating T cells and dendritic cells were significantly expanded in S-1-treated mice. 5-FU suppressed the ability of tumor cells to recruit MDSCs, while it did not suppress the survival and differentiation of mouse MDSCs in vitro. We also revealed that 5-FU or S-1 significantly downregulated the expression of tumor-derived Bv8 and S100A8. The knockdown of Bv8 or S100A8 in tumor cells suppressed tumor growth and MDSC recruitment in vivo. Furthermore, in comparison with pemetrexed, administration of S-1 improved the synergistic therapeutic efficacy of anti-PD-1 antibodies with or without carboplatin. Our findings revealed a novel mechanism wherein S-1 primed a favorable tumor microenvironment to provide the rationale for combination therapy with S-1 and ICIs as the optimal therapy for thoracic cancer. (キーワード) Mice / Animals / Myeloid-Derived Suppressor Cells / Calgranulin A / Tリンパ球 (T lymphocytes) / Thoracic Neoplasms / Lung Neoplasms / Tumor Microenvironment / Cell Line, Tumor (徳島大学機関リポジトリ) ● Metadata: 2011052 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/cas.15620 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36285504 ● Search Scopus @ Elsevier (PMID): 36285504 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15620 (徳島大学機関リポジトリ: 2011052, DOI: 10.1111/cas.15620, PubMed: 36285504)
11.	Masaki Hanibuchi, Atsushi Mitsuhashi, Tatsuya Kajimoto, Atsuro Saijo, Seidai Satou, Tetsuya Kitagawa and Yasuhiko Nishioka : Clinical significance of fractional exhaled nitric oxide and periostin as potential markers to assess therapeutic efficacy in patients with cough variant asthma., Respiratory Investigation, 61, 1, 16-22, 2023. (要約) Our observations indicate the usefulness of FeNO and periostin as potential "therapeutic" markers for CVA. To the best of our knowledge, this is the first report demonstrating the clinical significance of these factors as potential biomarkers to assess therapeutic efficacy in patients with CVA. (キーワード) Humans / Cough / Fractional Exhaled Nitric Oxide Testing / Prospective Studies / Clinical Relevance / ROC Curve / 一酸化窒素 (nitric oxide) / Exhalation / Asthma / Biomarkers / Breath Tests (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.resinv.2022.10.006 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36463016 ● Search Scopus @ Elsevier (PMID): 36463016 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2022.10.006 (DOI: 10.1016/j.resinv.2022.10.006, PubMed: 36463016)
12.	Seiya Ichihara, Hirokazu Ogino, Hiroto Yoneda, Keiko Haji, Kozo Kagawa, Kojin Murakami, Masato Mima, Yu Aoi, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Seidai Satou, Hiroshi Nokihara and Yasuhiko Nishioka : Immune checkpoint inhibitor-related pneumonitis with atypical radiologic features in a patient with anti-aminoacyl-tRNA synthetase antibody., Respiratory Medicine Case Reports, 41, 101797, 2023. (要約) A man with non-small-cell lung cancer who was negative for anti-nuclear antibodies was admitted for dyspnea after immune checkpoint inhibitor (ICI) administration. Computed tomography (CT) showed complexed radiologic features, including subpleural and basal predominant reticular shadow with cystic structures and peribronchovascular consolidation. Although we treated him with high-dose steroid under a diagnosis of ICI-related pneumonitis, he developed acute exacerbation of pneumonitis with progressive fibrosis and volume loss. A re-evaluation identified anti-aminoacyl-tRNA synthetase antibody in the serum collected before ICI administration. This case highlights the importance of re-evaluating pre-existing autoimmune disorders in patients who develop ICI-related pneumonitis with atypical radiologic features. (徳島大学機関リポジトリ) ● Metadata: 2011771 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.rmcr.2022.101797 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36583061 ● Search Scopus @ Elsevier (PMID): 36583061 ● Search Scopus @ Elsevier (DOI): 10.1016/j.rmcr.2022.101797 (徳島大学機関リポジトリ: 2011771, DOI: 10.1016/j.rmcr.2022.101797, PubMed: 36583061)
13.	Makoto Tobiume, Atsushi Mitsuhashi, Atsuro Saijo, Hirokazu Ogino, Tania Afroj, Hirohisa Ogawa, Hisatsugu Goto, Seidai Satou, Akane Abe, Keiko Haji, Ryohiko Ozaki, Hiromitsu Takizawa and Yasuhiko Nishioka : Analysis of the chemotactic factors for tumor-infiltrating fibrocytes and their prognostic significances in lung cancer., Oncology Letters, 24, 5, 417, 2022. (要約) Fibrocytes, which are bone marrow-derived collagen-producing cells, have been reported to be involved in pathogenesis of pulmonary fibrosis. Our previous study reported that tumor-infiltrating fibrocytes play a role in tumor progression and drug resistance in lung cancer. The present study therefore examined chemotactic factors for fibrocytes in tissues of non-small cell lung cancer (NSCLC) and their prognostic significance. Surgically resected tumor tissues were examined for the expression of chemotactic factors, including C-X-C motif chemokine 12 (CXCL12), CCL2, platelet-derived growth factor (PDGF)-AA and PDGF-BB, as well as tumor-infiltrating fibrocytes by immunostaining. The chemotactic ability of fibrocytes in response to each factor was evaluated using a migration assay by counting the migrated cells microscopically, and expression of receptors for chemotactic factors were analyzed by flow cytometry. The expression of CXCL12, but not CCL2, PDGF-AA, or PDGF-BB, was associated with the number of tumor-infiltrating fibrocytes in lung adenocarcinoma (LUAD), but not lung squamous cell carcinoma (LUSQ). In addition, patients with an increased expression of CXCL12 in LUAD but not LUSQ showed a significantly poorer prognosis compared with those with a decreased expression. However, the expression of CCL2, PDGF-AA and PDGF-BB was not correlated with the prognosis of patients with NSCLC. The number of fibrocytes was associated with a poor prognosis in LUAD. Fibrocytes derived from the peripheral blood of healthy subjects as well as patients with lung cancer expressed higher levels of CXCR4 compared with CCR2, PDGF and receptor-α and receptor-β. Overall, these results suggested that targeting tumor-infiltrating fibrocytes via the CXCL12/CXCR4 axis may be a useful strategy for controlling the progression of NSCLC, particularly LUAD. (出版サイトへのリンク) ● Publication site (DOI): 10.3892/ol.2022.13537 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36245829 ● Search Scopus @ Elsevier (PMID): 36245829 ● Search Scopus @ Elsevier (DOI): 10.3892/ol.2022.13537 (DOI: 10.3892/ol.2022.13537, PubMed: 36245829)
14.	Kenji Otsuka, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease., Thoracic Cancer, 13, 21, 2978-2984, 2022. (要約) Thirty-five patients received two or more regimens. Thirty-four patients were male and the median age at the initiation of second-line chemotherapy was 70 years. Almost all patients had a smoking history. Fourteen patients had adenocarcinoma and 15 had squamous cell carcinoma histology. Stages III and IV were observed in 20 and 11 patients, respectively. With respect to the type of ILD, 12 patients had usual interstitial pneumonia (UIP). The overall response rate and disease control rate were 11.4 and 68.6%, respectively. The median progression-free and median overall survival were 4.1 and 6.4 months, respectively. The AE of ILD was observed in eight patients, five of whom died. UIP and low percentage vital capacity were detected as significant risk factors for the AE of ILD. (キーワード) Humans / 男性 (male) / Aged / 女性 (female) / Carcinoma, Non-Small-Cell Lung / Lung Neoplasms / Retrospective Studies / Lung Diseases, Interstitial / Antineoplastic Combined Chemotherapy Protocols (徳島大学機関リポジトリ) ● Metadata: 2011344 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/1759-7714.14645 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36106507 ● Search Scopus @ Elsevier (PMID): 36106507 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.14645 (徳島大学機関リポジトリ: 2011344, DOI: 10.1111/1759-7714.14645, PubMed: 36106507)
15.	Masaki Hanibuchi, Atsuro Saijo, Atsushi Mitsuhashi, Tatsuya Kajimoto, Tetsuya Kitagawa and Yasuhiko Nishioka : The efficacy of mass screening for chronic obstructive pulmonary disease using screening questionnaires in a medical health check-up population., Respiratory Investigation, 60, 6, 815-821, 2022. (要約) Mass screening for COPD using screening questionnaires, particularly the COPD-PS questionnaire, might be useful to identify the early stages of COPD in a medical health check-up population. (キーワード) Humans / Forced Expiratory Volume / Cross-Sectional Studies / Reproducibility of Results / Pulmonary Disease, Chronic Obstructive / Spirometry / Mass Screening / Surveys and Questionnaires (徳島大学機関リポジトリ) ● Metadata: 2011770 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.resinv.2022.07.005 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36057534 ● Search Scopus @ Elsevier (PMID): 36057534 ● Search Scopus @ Elsevier (DOI): 10.1016/j.resinv.2022.07.005 (徳島大学機関リポジトリ: 2011770, DOI: 10.1016/j.resinv.2022.07.005, PubMed: 36057534)
16.	Hiroshi Nokihara, Hirokazu Ogino, Atsushi Mitsuhashi, Kensuke Kondo, Ei Ogawa, Ryohiko Ozaki, Yohei Yabuki, Hiroto Yoneda, Kenji Otsuka and Yasuhiko Nishioka : Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion., BMC Cancer, 22, 1, 2022. (要約) A total of 63 patients with EGFR mutated NSCLC were treated with osimertinib; 33 (12 with PE) had no EGFR T790M mutation, while 30 (12 with PE) had EGFR T790M mutation. In EGFR T790M-negative NSCLC, the progression-free survival (PFS) of the patients with PE was comparable to that of the patients without PE (median PFS 19.8 vs. 19.8 months, p = 0.693). In EGFR T790M- positive NSCLC, the PFS and overall survival (OS) of the patients with PE were significantly shorter than those of the patients without PE (median PFS 16.8 vs. 8.3 months, p = 0.003; median OS 44.9 vs. 14.2 months, p = 0.007). In the multivariate analysis, the presence of PE was independently associated with shorter PFS and OS in EGFR T790M-positive NSCLC patients, but not EGFR T790M-negative patients. (キーワード) Acrylamides / Aniline Compounds / Carcinoma, Non-Small-Cell Lung / ErbB Receptors / Humans / Lung Neoplasms / Mutation / Pleural Effusion / Protein Kinase Inhibitors / Retrospective Studies (徳島大学機関リポジトリ) ● Metadata: 2010117 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12885-022-09701-2 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35650550 ● Search Scopus @ Elsevier (PMID): 35650550 ● Search Scopus @ Elsevier (DOI): 10.1186/s12885-022-09701-2 (徳島大学機関リポジトリ: 2010117, DOI: 10.1186/s12885-022-09701-2, PubMed: 35650550)
17.	Yutaka Morita, Atsuro Saijo, Hiroshi Nokihara, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Yoshimi Bando and Yasuhiko Nishioka : Radiation therapy induces an abscopal effect and upregulates programmed death-ligand 1 expression in a patient with non-small cell lung cancer., Thoracic Cancer, 13, 7, 1079-1082, 2022. (要約) T cells, occasionally resulting in a systemic immune response to the tumor outside of the treatment field. The phenomenon of tumor regression at the site distant from irradiated fields is known as the abscopal effect. Several case reports have indicated a potential role of RT in overcoming primary and acquired resistance against immune checkpoint inhibitors in non-small cell lung cancer (NSCLC) and melanoma patients. We herein report an NSCLC patient who developed acquired resistance to an RT-induced abscopal effect and subsequently experienced reactivation of the systemic antitumor immune response by pembrolizumab, an antiprogrammed death 1 antibody. In this case, RT not only induced an abscopal effect but also upregulated the programmed death-ligand 1 expression outside of the irradiated field when the patient developed resistance to the abscopal effect. This case can facilitate our understanding of the mechanism underlying the RT-induced systemic immune response against cancer cells and adaptive resistance mechanism of cancer cells from immune surveillance. These findings highlight the promising results of current clinical trials combining RT and immune checkpoint inhibitors. Ongoing clinical trials will further establish evidence supporting combination therapy with RT and immune checkpoint inhibitors. (キーワード) B7-H1 Antigen / CD8-Positive T-Lymphocytes / Carcinoma, Non-Small-Cell Lung / Humans / Lung Neoplasms (徳島大学機関リポジトリ) ● Metadata: 2010209 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/1759-7714.14330 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35064748 ● Search Scopus @ Elsevier (PMID): 35064748 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.14330 (徳島大学機関リポジトリ: 2010209, DOI: 10.1111/1759-7714.14330, PubMed: 35064748)
18.	Masahiro Sako, Hiroshi Nokihara, Kensuke Kondo, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Akane Abe, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka, Hisanori Uehara and Yasuhiko Nishioka : A case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia successfully treated with pembrolizumab., Thoracic Cancer, 13, 1, 129-132, 2021. (要約) Pulmonary pleomorphic carcinoma is often refractory to chemotherapy and follows an aggressive clinical course. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, and a few cases with pleomorphic carcinoma have been reported to show tumor shrinkage after therapy with ICIs. When treating patients with ICIs, patient selection is essential, and monitoring and management of immune-related adverse events, including pneumonitis, are needed. We herein report a case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia treated with pembrolizumab, antiprogrammed cell death 1 antibody. Our report highlights important considerations necessary when treating advanced pleomorphic carcinoma patients complicated with interstitial pneumonia. We also review the literature regarding the use of ICIs in such patients. (キーワード) Aged / Antibodies, Monoclonal, Humanized / Carcinoma, Non-Small-Cell Lung / Humans / Immune Checkpoint Inhibitors / Lung Diseases, Interstitial / Lung Neoplasms / 男性 (male) (徳島大学機関リポジトリ) ● Metadata: 2010210 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/1759-7714.14243 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34859591 ● Search Scopus @ Elsevier (PMID): 34859591 ● Search Scopus @ Elsevier (DOI): 10.1111/1759-7714.14243 (徳島大学機関リポジトリ: 2010210, DOI: 10.1111/1759-7714.14243, PubMed: 34859591)
19.	Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka : Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma., BMC Pulmonary Medicine, 21, 1, 2021. (要約) Eleven patients received treatment with nivolumab. Objective response rate was 18.2% and the disease control rate was 90.9%. Median PFS was 6.8 months (95% confidence interval, 1.3 to 11.9 months) and median OS was 15.2 months (95% confidence interval, 8.9 to 21.5 months). IrAEs occurred in eight patients (72.7%), and grade ≥ 2 irAEs occurred in six patients (54.5%). PFS and OS were significantly longer in the grade ≥ 2 irAEs group than in grade < 2 irAEs group (median PFS 13.6 vs. 3.8 months, p = 0.0093; median OS not reached vs. 8.6 months, p = 0.0108). (キーワード) Aged / Aged, 80 and over / Antineoplastic Agents, Immunological / 女性 (female) / Humans / Immune System Diseases / Male / Mesothelioma, Malignant / Middle Aged / Nivolumab / Retrospective Studies / Survival Analysis / Treatment Outcome (徳島大学機関リポジトリ) ● Metadata: 2010118 (出版サイトへのリンク) ● Publication site (DOI): 10.1186/s12890-021-01746-6 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34781910 ● Search Scopus @ Elsevier (PMID): 34781910 ● Search Scopus @ Elsevier (DOI): 10.1186/s12890-021-01746-6 (徳島大学機関リポジトリ: 2010118, DOI: 10.1186/s12890-021-01746-6, PubMed: 34781910)
20.	Atsushi Mitsuhashi, Kensuke Kondoh, Kazuki Horikawa, Kazuya Koyama, Thi Na Nguyen, Tania Afroj, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino, Hiroshi Nokihara, Tsutomu Shinohara and Yasuhiko Nishioka : Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker., Cancer Science, 112, 12, 4853-4866, 2021. (要約) Immune checkpoint inhibitor (ICI) programmed death (PD)-1/PD-ligand 1 (PD-L1) blockade has been approved for various cancers. However, the underlying antitumor mechanisms mediated by ICIs and the predictive biomarkers remain unclear. We report the effects of anti-PD-L1/PD-1 Ab in tumor angiogenesis. In syngeneic mouse models, anti-PD-L1 Ab inhibited tumor angiogenesis and induces net-like hypoxia only in ICI-sensitive cell lines. In tumor tissue and serum of ICI-sensitive cell line-bearing mice, interferon-γ (IFN-γ) inducible angiostatic chemokines CXCL10/11 were upregulated by PD-L1 blockade. In vitro, CXCL10/11 gene upregulation by IFN-γ stimulation in tumor cell lines correlated with the sensitivity of PD-L1 blockade. The CXCL10/11 receptor CXCR3-neutralizing Ab or CXCL11 silencing in tumor cells inhibited the antiangiogenic effect of PD-L1 blockade in vivo. In pretreatment serum of lung carcinoma patients receiving anti-PD-1 Ab, the concentration of CXCL10/11 significantly correlated with the clinical outcome. Our results indicate the antiangiogenic function of PD-1/PD-L1 blockade and identify tumor-derived CXCL10/11 as a potential circulating biomarker of therapeutic sensitivity. (キーワード) Animals / B7-H1 Antigen / Biomarkers, Tumor / Carcinoma, Non-Small-Cell Lung / Cell Line, Tumor / Chemokine CXCL10 / Chemokine CXCL11 / HEK293 Cells / Humans / Immune Checkpoint Inhibitors / Interferon-gamma / Lung Neoplasms / 男性 (male) / Mice, Inbred BALB C / Mice, Inbred C57BL / Mice, Inbred CBA / Mice, Nude / Neoplasms, Experimental / Neovascularization, Pathologic / Programmed Cell Death 1 Receptor / RNA Interference (徳島大学機関リポジトリ) ● Metadata: 2010137 (出版サイトへのリンク) ● Publication site (DOI): 10.1111/cas.15161 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34628702 ● Search Scopus @ Elsevier (PMID): 34628702 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15161 (徳島大学機関リポジトリ: 2010137, DOI: 10.1111/cas.15161, PubMed: 34628702)
21.	Tania Afroj, Atsushi Mitsuhashi, Hirokazu Ogino, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Makoto Tobiume, Thi Na Nguyen, Hisatsugu Goto, Kazuya Koyama, Masamichi Sugimoto, Osamu Kondoh, Hiroshi Nokihara and Yasuhiko Nishioka : Blockade of PD-1/PD-L1 Pathway Enhances the Antigen-Presenting Capacity of Fibrocytes., The Journal of Immunology, 206, 6, 1204-1214, 2021. (要約) T cells when the activity is further enhanced by PD-L1/PD-1 blockade. (徳島大学機関リポジトリ) ● Metadata: 2008916 (出版サイトへのリンク) ● Publication site (DOI): 10.4049/jimmunol.2000909 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33504617 ● Search Scopus @ Elsevier (PMID): 33504617 ● Search Scopus @ Elsevier (DOI): 10.4049/jimmunol.2000909 (徳島大学機関リポジトリ: 2008916, DOI: 10.4049/jimmunol.2000909, PubMed: 33504617)
22.	Kenji Otsuka, Atsushi Mitsuhashi, Hisatsugu Goto, Masaki Hanibuchi, Kazuya Koyama, Hirohisa Ogawa, Hirokazu Ogino, Atsuro Saijo, Hiroyuki Kozai, Hiroto Yoneda, Makoto Tobiume, Masatoshi Kishuku, Keisuke Ishizawa and Yasuhiko Nishioka : Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells., Lung Cancer, 146, 86-96, 2020. (要約) The combination of anti-PD-1 antibody with CDDP + PEM may be a promising therapy for MPM via inhibiting the accumulation of MDSCs and vessels in tumors. (キーワード) Animals / Cell Line, Tumor / Lung Neoplasms / Mesothelioma / Mice / Myeloid-Derived Suppressor Cells / Pemetrexed (徳島大学機関リポジトリ) ● Metadata: 2008258 (出版サイトへのリンク) ● Publication site (DOI): 10.1016/j.lungcan.2020.05.023 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32526602 ● Search Scopus @ Elsevier (PMID): 32526602 ● Search Scopus @ Elsevier (DOI): 10.1016/j.lungcan.2020.05.023 (徳島大学機関リポジトリ: 2008258, DOI: 10.1016/j.lungcan.2020.05.023, PubMed: 32526602)

総説・解説:

1.	Atsushi Mitsuhashi and Yasuhiko Nishioka : Fibrocytes in tumor microenvironment: Identification of their fraction and novel therapeutic strategy, Cancer Science, 116, 1, 21-28, Jan. 2025. (要約) Fibrocytes were identified as bone marrow-derived myeloid cells that also have fibroblast-like phenotypes, such as ECM production and differentiation to myofibroblasts. Although fibrocytes are known to contribute to various types of tissue fibrosis, their functions in the tumor microenvironment are unclear. We focused on fibrocytes as pivotal regulators of tumor progression. Our previous studies have indicated that fibrocytes induce angiogenesis and cancer stem cell-like phenotypes by secreting various growth factors. In contrast, immune checkpoint inhibitor (ICI)-treated fibrocytes demonstrated antigen-presenting capacity and enhanced antitumor T cell proliferation. Taken together, these findings indicate that fibrocytes have multiple effects on tumor progression. However, the detailed phenotypes of fibrocytes have not been fully elucidated because the isolation of distinct fibrocyte clusters has not been achieved without culturing in ECM-coated conditions or intracellular staining of ECM. The development of single-cell analyses partially resolves these problems. Single-cell RNA sequences in CD45⁺ immune cells from tumor tissue identified ECM-expressing myeloid-like cells as distinct fibrocyte clusters. In addition, these findings enabled the isolation of tumor-infiltrating fibrocytes as CD45⁺CD34⁺ cells. These tumor-infiltrating fibrocytes demonstrated both antigen-presenting ability and differentiation into myofibroblast-like cancer-associated fibroblasts. Considering these functions of fibrocytes in tumor progression, molecular-targeting agents for the migration, activity, and differentiation of fibrocytes are promising therapeutic strategies. Furthermore, identification of specific cell surface markers and master regulators of fibrocytes will advance novel fibrocyte-targeting therapies. In this review, we discuss the multiple roles of tumor-infiltrating fibrocytes and novel cancer therapeutic strategies. (キーワード) angiogenesis / cancer stem cell / cancer-associated fibroblast / fibrocyte / immune checkpoint inhibitor (出版サイトへのリンク) ● Publication site (DOI): 10.1111/cas.16385 (文献検索サイトへのリンク) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39492802 ● Summary page in Scopus @ Elsevier: 2-s2.0-85208031303 (DOI: 10.1111/cas.16385, PubMed: 39492802, Elsevier: Scopus)
2.	三橋惇志, 西岡安彦 : 1細胞解析による腫瘍内fibrocyteの同定, 細胞, 55, 1, 55-59, 2023年6月.
3.	三橋惇志, 西岡安彦 : 血管新生阻害剤に対する耐性獲得メカニズム, 実験医学, 38, 15, 157-162, 2020年9月. (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1010853567272655106 (CiNii: 1010853567272655106)
4.	三橋惇志, 西岡安彦 : 免疫チェックポイント阻害薬の効果を増強する併用療法, 分子呼吸器病, 23, 1, 49-53, 2019年3月. (キーワード) 免疫チェックポイント阻害薬 / 化学療法 / 血管新生阻害薬 (文献検索サイトへのリンク) ● CiNii @ 国立情報学研究所 (CRID): 1521417755561804800 (CiNii: 1521417755561804800)

国際会議:

1.	Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yuko Toyoda, Yugo Matsumura, Seiya Ichihara, Takeshi Imakura, Rikako Matsumoto, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Kayoko Hase, Eiji Takeuchi, Takashi Haku and Yasuhiko Nishioka : The Conflicting Impacts of G-CSF on the Therapeutic Efficacy of Chemoimmunotherapy for Extensive Stage Small Cell Lung Cancer, 2024 World Conference on Lung Cancer, San Diego, Sep. 2024.
2.	Hirokazu Ogino, Na Thi Nguyen, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroshi Nokihara, Masaki Hanibuchi and Yasuhiko Nishioka : The potential of fluoropyrimidine to be an immunologically optimal partner of immunotherapy for thoracic malignancies, 2024 World Conference on Lung Cancer, San Diego, Sep. 2024.
3.	Atsushi Mitsuhashi, Kazuya Koyama, Afroj Tania, Atsuro Saijo, Makoto Tobiume, Hirokazu Ogino, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka : The identification and analysis of fibrocyte regulating the tumor immune microenvironment, The 9th Joint Meeting 2023 (Tokushima Univ., Gifu Univ., SNU, and IBS-KAIST)., Daejeon, Oct. 2023.
4.	Kazuya Koyama, Seidai Satou, Hiroshi Kawano, Hiroshi Kawano, Atsushi Mitsuhashi, Murakami Kojin, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Hirohisa Ogawa and Yasuhiko Nishioka : Evaluation of fibrocytes in silica-induced and bleomycin-induced pulmonary fibrosis model in mice by single cell RNA-seq analysis, APSR 2022, Seoul, Nov. 2022.
5.	Yabuki Yohei, Kenji Otsuka, Hirokazu Ogino, Takeuchi Eiji, Haku Takashi, Takanori Kanematsu, Nishimura Naoki, Yuko Toyoda, Masaki Hanibuchi, Atsushi Mitsuhashi, Tsukazaki Yuki, Ryohiko Ozaki, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka : A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with advanced or recurrent non-squamous non-small cell lung cancer, APSR 2022, Seoul, Nov. 2022.
6.	Ryohiko Ozaki, Hiroshi Nokihara, Yabuki Youhei, Atsushi Mitsuhashi, Hiroto Yoneda, Kenji Otsuka, Hirokazu Ogino and Yasuhiko Nishioka : The examination of the second-line chemotherapy in SCLC patients with interstitial lung disease, ERS International Congress 2022, Barcelona, Sep. 2022.
7.	Kazuya Koyama, Hiroshi Kawano, Atsushi Mitsuhashi, Kojin Murakami, Takeshi Imakura, Yuya Yamashita, Keiko Haji, Kozo Kagawa, Seidai Satou, Hirohisa Ogawa and Yasuhiko Nishioka : Single Cell RNA-seq Analysis of Fibrocytes in Silica Induced Mouse Pulmonary Fibrosis Model, ATS 2022 International Conference, San Francisco, May 2022.
8.	Nguyen Na Thi, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Afroj Tania, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka : S-1 reduces myeloid-derived suppressor cells in murine mesothelioma model and enhances the anti-tumor activity of anti-PD-1 antibody, APSR 2021, Kyoto and online, Nov. 2021.
9.	Ryohiko Ozaki, Hiroshi Nokihara, Atsushi Mitsuhashi, Kondou Kensuke, YABUKI Yohhei, Hiroto Yoneda, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka : The clinical efficacy and safety of the second-line chemotherapy in extensive-disease small cell lung cancer patients with interstitial lung disease, APSR 2021, Kyoto and online, Nov. 2021.
10.	Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, YABUKI Yohhei, Hirokazu Ogino, Kenji Otsuka and Yasuhiko Nishioka : Association of immune-related adverse events with therapeutic response to Nivolumab in patients with malignant pleural mesothelioma, APSR 2021, Kyoto and online, Nov. 2021.
11.	Hirokazu Ogino, Afroj Tania, Atsushi Mitsuhashi, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Nguyen Thi Na, Kozo Kagawa, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka : Antigen-presenting capacity of fibrocytes and its regulation by anti-PD-1/PD-L1 antibodies, APSR 2021, Kyoto and online, Nov. 2021.
12.	Atsushi Mitsuhashi, Afroj Tania, Atsuro Saijo, Kenji Otsuka, Hiroto Yoneda, Kazuya Koyama, Sugimoto Masamichi, Kondoh Osamu, Hiroshi Nokihara and Yasuhiko Nishioka : The role of fibrocyte-like cells in combination treatment of immune checkpoint inhibitor with antiangiogenic agents, ERS International Congress 2020 Virtual, WEB, Sep. 2020. (出版サイトへのリンク) ● Publication site (DOI): 10.1183/13993003.congress-2020.1134 (文献検索サイトへのリンク) ● Search Scopus @ Elsevier (DOI): 10.1183/13993003.congress-2020.1134 (DOI: 10.1183/13993003.congress-2020.1134)

国内講演発表:

1.	塚﨑佑貴, 荻野広和, 岡野義夫, 柿内聡司, 豊田優子, 松本利加子, 尾崎領彦, 森田優, 三橋惇志, 矢葺洋平, 埴淵昌毅, 長谷加容子, 竹内栄治, 葉久貴司, 西岡安彦 : G-CSFが進展型小細胞肺癌における化学免疫療法の治療効果に及ぼす影響を検討した多施設共同後方視的解析, 第65回日本肺癌学会学術集会, 2024年11月.
2.	矢葺洋平, 三橋惇志, 荻野広和, 尾崎領彦, 塚﨑佑貴, 埴淵昌毅, 西岡安彦 : IFN-γ反応性ケモカイン産生制御機序の解明と新規複合がん免疫療法への応用, 第65回日本肺癌学会学術集会, 2024年11月.
3.	三橋惇志, 荻野広和, 矢葺洋平, 尾崎領彦, 塚﨑佑貴, 埴淵昌毅, 軒原浩, 西岡安彦 : Fibrocyte 分化制御による免疫排除克服と新規複合がん免疫療法への展開, 第65回日本肺癌学会学術集会, 2024年10月.
4.	塚﨑佑貴, 荻野広和, 岡野義夫, 柿内聡司, 豊田優子, 松本利加子, 尾崎領彦, 森田優, 三橋惇志, 矢葺洋平, 埴淵昌毅, 長谷加容子, 竹内栄治, 葉久貴司, 西岡安彦 : G-CSF が進展型小細胞肺癌に対する化学免疫療法の治療効果に及ぼす影響に関する解析, 第62回日本癌治療学会学術集会, 2024年10月.
5.	三橋惇志, 小山壱也, 荻野広和, 矢葺洋平, 尾崎領彦, 塚﨑佑貴, 森田優, 吉田碧人, 軒原浩, 埴淵昌毅, 西岡安彦 : Fibrocyte 制御によるがん免疫排除克服に向けた治療戦略, 第83回日本癌学会学術総会, 2024年9月.
6.	三橋惇志, 荻野広和, 矢葺洋平, 尾崎領彦, 軒原浩, 西岡安彦 : Fibrocyte 分化を標的とした免疫排除克服への新規治療探索, 第28回日本がん分子標的治療学会学術集会, 2024年6月.
7.	塚﨑佑貴, 飛梅亮, 三橋惇志, 尾崎領彦, 矢葺洋平, 米田浩人, 荻野広和, 埴淵昌毅, 小川博久, 滝沢宏光, 西岡安彦 : 線維細胞の腫瘍内浸潤およびそれを誘導する走化因子が非小細胞肺癌の予後に及ぼす影響についての解析, 第64回日本呼吸器学会学術講演会, 2024年4月.
8.	荻野広和, Nguyen Thi Na, 香西博之, 三橋惇志, 塚﨑佑貴, 矢葺洋平, 尾崎領彦, 埴淵昌毅, 西岡安彦 : 胸部腫瘍に対して免疫チェックポイント阻害薬と併用すべき至適抗がん剤の同定を目指した免疫学的解析, 第64回日本呼吸器学会学術講演会, 2024年4月.
9.	Yuki Tsukazaki, Hirokazu Ogino, Yoshio Okano, Soji Kakiuchi, Shoko Harada, Yugo Matumura, Seiya Ichihara, Takeshi Imakura, Ryohiko Ozaki, Ei Ogawa, Yutaka Morita, Atsushi Mitsuhashi, Yohei Yabuki, Hiroto Yoneda, Masaki Hanibuchi, Yuko Toyoda, Kayoko Hase, Eiji Takeuchi, Takashi Haku and Yasuhiko Nishioka : The impacts of G-CSF on the therapeutic efficacy of chemo-immunotherapy for extensive-stage small cell lung cancer., 2024 the Japanese Society of Medical Oncology Annual Meeting (JSMO2024), Feb. 2024.
10.	Hirokazu Ogino, Nguyen Na Thi, Hiroyuki Kozai, Atsushi Mitsuhashi, Yuki Tsukazaki, Yohei Yabuki, Ryohiko Ozaki, Hiroshi Nokihara, Masaki Hanibuchi and Yasuhiko Nishioka : Fluoropyrimidine has a potential to be an immunologically optimal partner ofimmunotherapy for thoracic malignancies., 2024 the Japanese Society of Medical Oncology Annual Meeting (JSMO2024), Feb. 2024.
11.	塚﨑佑貴, 飛梅亮, 三橋惇志, 尾崎領彦, 矢葺洋平, 米田浩人, 荻野広和, 埴淵昌毅, 小川博久, 滝沢宏光, 西岡安彦 : 非小細胞肺癌症例における腫瘍浸潤線維細胞の走化因子と疾患予後との関連性についての解析, 第64回日本肺癌学会学術集会, 2023年11月.
12.	荻野広和, 香西博之, 三橋惇志, 塚﨑佑貴, 矢葺洋平, 尾崎領彦, 米田浩人, 埴淵昌毅, 軒原浩, 西岡安彦 : フッ化ピリミジンは胸部腫瘍の免疫原性細胞死を誘導し免疫チェックポイント阻害薬の至適併用薬となり得る, 第64回日本肺癌学会学術集会, 2023年11月.
13.	尾崎領彦, 軒原浩, 塚﨑佑貴, 矢葺洋平, 三橋惇志, 米田浩人, 荻野広和, 西岡安彦 : 進展型小細胞肺癌において2次治療が受けられない患者の臨床的背景の検討, 第64回日本肺癌学会学術集会, 2023年11月.
14.	三橋惇志, 荻野広和, 米田浩人, 軒原浩, 西岡安彦 : 胸部腫瘍におけるfibrocyteの同定と新規治療標的としての展開, 第64回日本肺癌学会学術集会, 2023年11月.
15.	佐藤正大, 埴淵昌毅, 三橋惇志, 西岡安彦 : 咳喘息治療における効果予測バイオマーカーの探索, 第72回日本アレルギー学会学術大会, 2023年10月.
16.	尾崎領彦, 小川瑛, 軒原浩, 三橋惇志, 矢葺洋平, 米田浩人, 荻野広和, 西岡安彦 : ALK融合遺伝子陽性非小細胞肺癌の効果予測因子に関する検討, 第61回日本癌治療学会学術集会, 2023年10月.
17.	矢葺洋平, 三橋惇志, 荻野広和, Na T. Nguyen, 米田浩人, 尾崎領彦, 塚﨑佑貴, 埴淵昌毅, 軒原浩, 西岡安彦 : HIF1A 阻害による腫瘍細胞由来 CXCL10/11 制御を介した抗 PDL1 抗体への耐性克服, 第82回日本癌学会学術総会, 2023年9月.
18.	三橋惇志, 小山壱也, 荻野広和, 杉本正道, 根東攝, 軒原浩, 西岡安彦 : 腫瘍内 fibrocyte 遊走・分化制御がもたらす腫瘍免疫微小環境への影響, 第82回日本癌学会学術総会, 2023年9月.
19.	三橋惇志, 小山壱也, アフローズタニア, 西條敦郎, 飛梅亮, 荻野広和, 杉本正道, 根東攝, 軒原浩, 西岡安彦 : 腫瘍内 fibrocyte の同定と制御による新規がん治療開発への橋渡し研究, 第82回日本癌学会学術総会, 2023年9月.
20.	三橋惇志, 荻野広和, Nguyen Na Thi, 矢葺洋平, 米田浩人, 杉本正道, 根東攝, 軒原浩, 西岡安彦 : 腫瘍内fibrocyteの同定と機能制御による新規複合がん免疫療法の開発, 第32回日本がん転移学会学術集会・総会, 2023年7月.
21.	米田浩人, 三橋惇志, 荻野広和, 軒原浩, 阿部真治, 金子美華, 加藤幸成, 西岡安彦 : 悪性胸膜中皮腫に対する抗ポドプラニン抗体および抗CTLA-4抗体による複合がん免疫療法の検討, 第32回日本がん転移学会学術集会・総会, 2023年7月.
22.	塚﨑佑貴, 三橋惇志, 尾崎領彦, 矢葺洋平, 米田浩人, 荻野広和, 西岡安彦 : 肺癌における腫瘍浸潤線維細胞の走化因子とその疾患予後に及ぼす影響についての解析, 第27回日本がん分子標的治療学会学術集会, 2023年6月.
23.	三橋惇志, 荻野広和, Nguyen Na Thi, 米田浩人, 矢葺洋平, 杉本正道, 根東攝, 軒原浩, 西岡安彦 : Fibrocyte の分化制御による複合がん免疫療法への展開, 第27回日本がん分子標的治療学会学術集会, 2023年6月.
24.	矢葺洋平, 三橋惇志, Nguyen Na Thi, 荻野広和, 米田浩人, 尾崎領彦, 西岡安彦 : IFN-g 反応性ケモカイン産生制御機序の解明と新規複合がん免疫療法への応用, 第27回日本がん分子標的治療学会学術集会, 2023年6月.
25.	佐藤正大, 埴淵昌毅, 三橋惇志, 西岡安彦 : 咳喘息における呼気中一酸化窒素と血清ペリオスチンの臨床的意義の検討, 第63回日本呼吸器学会学術講演会, 2023年4月.
26.	埴淵昌毅, 三橋惇志, 西條敦郎, 佐藤正大, 西岡安彦 : スクリーニング質問票を用いたCOPD検診システムの有用性の検討, 第63回日本呼吸器学会学術講演会, 2023年4月.
27.	荻野広和, 尾崎領彦, 大塚憲司, 三橋惇志, 塚﨑佑貴, 矢葺洋平, 米田浩人, 軒原浩, 西岡安彦 : 間質性肺炎を合併する進行期肺癌に対する二次化学療法の有効性および安全性に関する検討, 第120回日本内科学会講演会, 2023年4月.
28.	Tsukazaki Yuki, Ogawa Ei, Hiroshi Nokihara, Atsushi Mitsuhashi, Kondo Kensuke, Yabuki Youhei, Ryohiko Ozaki, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : The prognostic factors for the efficacy of anaplastic lymphoma kinase inhibitors in non-small cell lung cancer, 2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023.
29.	Ryohiko Ozaki, Hiroshi Nokihara, Tukazaki Yuki, Yabuki Yohei, Atsushi Mitsuhashi, Hiroto Yoneda, Hirokazu Ogino and Yasuhiko Nishioka : Clinical factors of not receiving second-line chemotherapy in ED-SCLC patients, 2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023.
30.	Hirokazu Ogino, Kondo Kensuke, Atsushi Mitsuhashi, Tsukazaki Yuki, Ryohiko Ozaki, Yabuki Yohei, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka : The novel prognostic system for the efficacy of immune checkpoint inhibitors in non-small cell lung cancer, 2023 the Japanese Society of Medical Oncology Annual Meeting, Mar. 2023.
31.	中西颯斗, 土師恵子, 松村有悟, 三橋惇志, 小川瑛, 今倉健, 美馬正人, 尾崎領彦, 米田浩人, 荻野広和, 坂口暁, 佐藤正大, 埴淵昌毅, 西岡安彦 : 同時に異なる3つの組織型を認めた多発性肺癌の1例, 第67回日本呼吸器学会中国・四国地方会, 2022年12月.
32.	小川瑛, 軒原浩, 三橋惇志, 近藤健介, 塚崎佑貴, 矢葺洋平, 尾崎領彦, 米田浩人, 荻野広和, 西岡安彦 : ALK融合遺伝子陽性非小細胞肺癌の効果予測因子に関する検討, 第63回日本肺癌学会学術集会, 2022年12月.
33.	Na T. Nguyen, Atsushi Mitsuhashi, Hirokazu Ogino, Hiroyuki Kozai, Hiroto Yoneda, Hiroshi Nokihara and Yasuhiko Nishioka : Eliminates MDSCs and enhances the efficacy of immune checkpoint inhibitor in thoracic tumors, The 63rd Annual Meeting of the Japan Lung Cancer Society, Dec. 2022.
34.	軒原浩, 荻野広和, 三橋惇志, 近藤健介, 小川瑛, 尾崎領彦, 矢葺洋平, 米田浩人, 西岡安彦 : 胸水を伴うEGFR遺伝子変異陽性非小細胞肺がんに対するオシメルチニブの有効性の検討, 第63回日本肺癌学会学術集会, 2022年12月.
35.	尾崎領彦, 軒原浩, 塚崎佑貴, 矢葺洋平, 三橋惇志, 米田浩人, 荻野広和, 西岡安彦 : 間質性肺炎合併進展型小細胞肺癌における2次化学療法の有効性および安全性について, 第60回日本癌治療学会学術集会, 2022年10月.
36.	Atsushi Mitsuhashi, Hirokazu Ogino, Hiroshi Nokihara and Yasuhiko Nishioka : PD-1/PD-L1 blockade mediates antiangiogenic effects by tumorderived CXCL10/11 as a potential predictive biomarker, The 81st Annual Meeting of the Japanese Cancer Association, Sep. 2022.
37.	Atsushi Mitsuhashi, Hirokazu Ogino, Sugimoto Masamichi, Hiroshi Nokihara and Yasuhiko Nishioka : Fibrocyte drives antitumor immunity via T cell-costimulation in combination immunotherapy, The 81st Annual Meeting of the Japanese Cancer Association, Sep. 2022.
38.	三橋惇志, 荻野広和, Nguyen Thi Na, 米田浩人, 大塚憲司, 杉本正道, 根東攝, 軒原浩, 西岡安彦 : 免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内fibrocyteの機能解析, 第26回日本がん分子標的治療学会学術集会, 2022年6月.
39.	米田浩人, 三橋惇志, 荻野広和, 尾崎領彦, 矢葺洋平, 軒原浩, 阿部真治, 加藤幸成, 西岡安彦 : 悪性胸膜中皮腫に対する抗ポドプラニン抗体および抗CTLA-4抗体による複合がん免疫療法の検討, 第26回日本がん分子標的治療学会学術集会, 2022年6月.
40.	村上行人, 原田紗希, 今倉健, 三橋惇志, 小川瑛, 塚崎佑貴, 尾崎領彦, 矢葺洋平, 香川耕造, 米田浩人, 阿部あかね, 荻野広和, 小山壱也, 佐藤正大, 坂口暁, 西岡安彦 : 抗GM-CSF抗体測定が早期診断に有用であった自己免疫性肺胞蛋白症の一例, 第45回日本呼吸器内視鏡学会学術集会, 2022年5月.
41.	今倉健, 佐藤正大, 原田紗希, 三橋惇志, 小川瑛, 村上行人, 塚崎佑貴, 尾崎領彦, 矢葺洋平, 香川耕造, 米田浩人, 阿部あかね, 荻野広和, 坂口暁, 西岡安彦 : 肺門部・縦隔リンパ節腫大に対してEBUS-TBNAを実施し子宮頸癌再発と診断した1例, 第45回日本呼吸器内視鏡学会学術集会, 2022年5月.
42.	小山壱也, 三橋惇志, 今倉健, 村上行人, 香川耕造, 佐藤正大, 河野弘, 小川博久, 西岡安彦 : シングルセル解析を用いた肺線維症マウスモデルにおけるfibrocyteの検討, 第62回日本呼吸器学会学術講演会, 2022年4月.
43.	尾崎領彦, 軒原浩, 矢葺洋平, 三橋惇志, 米田浩人, 大塚憲司, 荻野広和, 西岡安彦 : Second-line chemotherapy for extensive-disease small cell lung cancer with interstitial lung disease, 第19回日本臨床腫瘍学会学術集会, 2022年2月.
44.	三橋惇志, 荻野広和, 米田浩人, 大塚憲司, 軒原浩, 西岡安彦 : 抗PD-1/PD-L1抗体による血管新生制御メカニズムの解析と治療効果予測バイオマーカーとしての応用, 第62回日本肺癌学会学術集会, 2021年11月.
45.	尾崎領彦, 軒原浩, 三橋惇志, 近藤健介, 矢葺洋平, 米田浩人, 荻野広和, 大塚憲司, 西岡安彦 : 間質性肺炎合併小細胞肺癌に対する二次化学療法の有効性及び安全性の検討, 第62回日本肺癌学会学術集会, 2021年11月.
46.	米田浩人, 軒原浩, 三橋惇志, 尾崎領彦, 矢葺洋平, 荻野広和, 大塚憲司, 西岡安彦 : 悪性胸膜中皮腫患者におけるニボルマブの免疫関連有害事象と治療効果の相関性, 第59回日本癌治療学会学術集会, 2021年10月.
47.	大塚憲司, 三橋惇志, 尾崎領彦, 矢葺洋平, 米田浩人, 荻野広和, 軒原浩, 竹内栄治, 杉浦八十生, 知花賢治, 田村厚久, 安宅信二, 西岡安彦 : 進展型小細胞肺癌における予後規定因子, 第59回日本癌治療学会学術集会, 2021年10月.
48.	三橋惇志, 荻野広和, 西條敦郎, 大塚憲司, 杉本正道, 軒原浩, 西岡安彦 : 免疫チェックポイント阻害薬および血管新生阻害薬併用療法におけるfibrocyteの役割, 第80回日本癌学会学術総会, 2021年10月.
49.	中内友合江, 矢葺洋平, 土師恵子, 米田浩人, 三橋惇志, 青井優, 石田卓也, 村上尚哉, 荻野広和, 佐藤正大, 軒原浩, 西岡安彦 : Tepotinibが著効したMET遺伝子exon14 skipping変異陽性肺腺癌の1例, 第59回日本肺癌学会中国・四国支部学術集会, 2021年8月.
50.	三橋惇志, 荻野広和, 米田浩人, 大塚憲司, 軒原浩, 西岡安彦 : 肺がん肝転移におけるspheroid形成がん幹細胞様分画の役割, 第30回日本がん転移学会学術集会・総会, 2021年7月.
51.	三橋惇志, Tania Afroj, NGUYEN NA THI, 荻野広和, 米田浩人, 大塚憲司, 軒原浩, 西岡安彦 : 抗PD-1/PD-L1抗体による腫瘍血管新生抑制メカニズムの解析と治療効果予測バイオマーカーとしての応用., 第25回日本がん分子標的治療学会学術集会, 2021年5月.
52.	Na Thi Nguyen, Atsushi Mitsuhashi, Hiroyuki Kozai, Hiroto Yoneda, Afroj Tania, Kenji Otsuka, Hiroshi Nokihara and Yasuhiko Nishioka : TS-1による腫瘍関連骨髄由来抑制細胞の制御を介した免疫チェックポイント阻害剤との併用効果の検討, 第25回日本がん分子標的治療学会学術集会, May 2021.
53.	近藤健介, 軒原浩, 佐藤正大, 三橋惇志, 米田浩人, 香西博之, 大塚憲司, 西岡安彦 : 非小細胞肺癌に対する免疫チェックポイント阻害剤の予後予測因子の検討, 第61回日本呼吸器学会学術講演会, 2021年4月.
54.	香西博之, 三橋惇志, 尾崎領彦, 米田浩人, 大塚憲司, 軒原浩, 西岡安彦 : 免疫原性細胞死を誘導する細胞傷害性抗癌剤についての検討, 第61回日本呼吸器学会学術講演会, 2021年4月.
55.	尾崎領彦, 三橋惇志, 米田浩人, 大塚憲司, 軒原浩, 西岡安彦, 櫻田巧, 石澤啓介 : ペメトレキセド投与後の皮疹に対するデキサメタゾン予防投与の効果の検討, 第18回日本臨床腫瘍学会学術集会, 2021年2月.
56.	三橋惇志, 櫻田巧, 合田光寛, 座間味義人, 米田浩人, 大塚憲司, 軒原浩, 石澤啓介, 西岡安彦 : ペメトレキセド投与後の皮疹に対する低用量デキサメタゾン予防効果の検討, 第61回日本肺癌学会学術集会, 2020年11月.
57.	大塚憲司, 三橋惇志, 米田浩人, 軒原浩, 竹内栄治, 知花賢治, 安宅信二, 田村厚久, 西岡安彦 : 進展型小細胞肺癌の予後規定因子の検討, 第61回日本肺癌学会学術集会, 2020年11月.
58.	櫻田巧, 三橋惇志, 米田浩人, 大塚憲司, 合田光寛, 座間味義人, 石澤啓介, 軒原浩, 西岡安彦 : ペメトレキセド投与後の皮疹に対する低用量のステロイド予防投与の前向き臨床試験, 第58回日本癌治療学会学術集会, 2020年10月.
59.	香西博之, 三橋惇志, 米田浩人, 大塚憲司, 軒原浩, 西岡安彦 : 細胞障害性抗がん剤による腫瘍免疫原性細胞死誘導能の検討, 第58回日本癌治療学会学術集会, 2020年10月.
60.	西條敦郎, 香西博之, 後東久嗣, 大塚憲司, 米田浩人, 三橋惇志, 西岡安彦 : 非小細胞肺がんに合併した悪性胸水に対する bevacizumab の有効性と耐性化機序の解析, 第24回日本がん分子標的治療学会学術集会, 2020年10月.
61.	Nguyen Thi Na, 三橋惇志, Tania Afroj, 米田浩人, 香西博之, 大塚憲司, 軒原浩, 西岡安彦 : マウス中皮腫細胞株皮下移植モデルにおける細胞障害性抗癌剤の腫瘍関連骨髄由来抑制細胞への影響, 第24回日本がん分子標的治療学会学術集会, 2020年10月.
62.	Tania Afroj, 荻野広和, 三橋惇志, 米田浩人, 香西博之, 大塚憲司, 軒原浩, 安倍正博, 西岡安彦 : 腫瘍免疫における線維細胞の免疫調節機能の検討, 第24回日本がん分子標的治療学会学術集会, 2020年10月.
63.	近藤健介, 軒原浩, 三橋惇志, 米田浩人, 香西博之, 大塚憲司, 西岡安彦 : 非小細胞肺癌における免疫チェックポイント阻害剤の予後予測因子の検討, 第24回日本がん分子標的治療学会学術集会, 2020年10月.
64.	三橋惇志, Tania Afroj, 荻野広和, Nguyen Thi Na, 米田浩人, 香西博之, 大塚憲司, 杉本正道, 根東攝, 軒原浩, 西岡安彦 : 免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内 fibrocyte-like cell の機能解析, 第24回日本がん分子標的治療学会学術集会, 2020年10月.
65.	香西博之, 三橋惇志, Nguyen Thi Na, Tania Afroj, 米田浩人, 大塚憲司, 軒原浩, 西岡安彦 : 肺癌において細胞障害性抗癌剤が免疫原性細胞死に与える影響についての検討, 第24回日本がん分子標的治療学会学術集会, 2020年10月.
66.	三橋惇志, 荻野広和, 西條敦郎, 大塚憲司, 杉本正道, 軒原浩, 西岡安彦 : 免疫チェックポイント阻害薬および血管新生阻害薬併用療法における腫瘍内 fibrocyte-like cell の機能解析, 第79回日本癌学会学術総会, 2020年10月.
67.	西岡安彦, 小山壱也, 三橋惇志, Afroj Tania, 河野弘 : 肺線維症モデルにおけるscRNA-Seqを用いた線維細胞の解析, 第60回日本呼吸器学会学術講演会(シンポジウム), 2020年9月.
68.	三橋惇志, 荻野広和, 木宿昌俊, 大塚憲司, 軒原浩, 西岡安彦 : 免疫チェックポイント阻害薬および血管新生阻害薬による複合がん免疫療法における腫瘍内fibrocytelike cellの機能解析, 第32回日本バイオセラピィ学会学術集会総会, 2019年11月.
69.	大塚憲司, 米田浩人, 三橋惇志, 荻野広和, 香西博之, 飛梅亮, 軒原浩, 西岡安彦 : 間質性肺炎合併非小細胞肺癌における2次化学療法の安全性と有効性の検討, 第57回日本癌治療学会学術集会, 2019年10月.
70.	西岡安彦, 荻野広和, 三橋惇志 : 血管新生阻害薬耐性とその克服, 第23回日本がん分子標的治療学会学術集会(シンポジウム), 2019年6月.
71.	三橋惇志, 後東久嗣, 荻野広和, 大塚憲司, 杉本正道, 根東攝, 西岡安彦 : 免疫チェックポイント阻害薬および血管新生阻害薬併用療法における fibrocyte-like cell の機能解析, 第23回日本がん分子標的治療学会学術集会, 2019年6月.
72.	三橋惇志, 飛梅亮, 荻野広和, 近藤真代, 豊田優子, 後東久嗣, 吉田光輝, 小川博久, 軒原浩, 西岡安彦 : 肺多形癌における上皮間葉転換 (EMT)の検討, 第120回日本内科学会四国地方会, 2019年5月.
73.	Afroj Tania, Hirokazu Ogino, Makoto Tobiume, Hiroto Yoneda, Kisyuku Masatoshi, Atsuro Saijo, Atsushi Mitsuhashi, Koyama Kazuya, Hisatsugu Goto and Yasuhiko Nishioka : Analyses of immuno-modulatory function of fibrocytes in tumor immunity, The 59th Annual Meeting of the Japanese Respiratory Society, Apr. 2019.
74.	荻野広和, 大塚憲司, 三橋惇志, 木宿昌俊, 西岡安彦 : 肺癌・悪性胸膜中皮腫マウスモデルを用いた免疫チェックポイント阻害薬と化学療法の併用効果に関する検討, 第31回日本バイオセラピィ学会学術集会総会, 2018年12月.
75.	後東久嗣, 三橋惇志, 西條敦郎, 西岡安彦 : 線維細胞(fibrocytes)を標的とした血管新生阻害薬耐性メカニズムの解明と治療への展開, 第59回日本肺癌学会学術集会, 2018年11月.
76.	髙橋直希, 荻野広和, 埴淵昌毅, 西條敦郎, 飛梅亮, 香西博之, 米田浩人, 福家麻美, 三橋惇志, 宮本憲哉, 軒原浩, 後東久嗣, 西岡安彦 : 当科における高齢者肺癌の臨床的検討, 第257回徳島医学会学術集会, 2018年8月.
77.	三橋惇志, 香川耕造, 米田浩人, 西條敦郎, 飛梅亮, 荻野広和, 近藤真代, 髙橋直希, 軒原浩, 後東久嗣, 西岡安彦 : 当科における免疫チェックポイント阻害薬による薬剤性間質性肺疾患の検討, 第59回日本呼吸器学会中国・四国地方会/第57回日本肺癌学会中国・四国支部学術集会, 2018年7月.

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

線維細胞のシングルセル解析が導く新規標的分子と肺がん及び肺線維症の革新的治療開発 (研究課題/領域番号: 25K02661 )
ヘパラナーゼ制御によるhot tumor誘導と新規がん複合免疫療法の創出 (研究課題/領域番号: 24K10287 )
腫瘍内線維細胞における時計遺伝子の機能解析と新規複合がん免疫療法開発への応用 (研究課題/領域番号: 23K06637 )
肺がん・中皮腫における新たな抗原提示細胞の同定から革新的複合がん免疫療法への展開 (研究課題/領域番号: 23K24340 )
腫瘍内免疫療法を用いた新規複合がん免疫療法の効果規定因子を同定する試み (研究課題/領域番号: 22K07304 )
抗PD-L1抗体による腫瘍内血管制御を介した新規腫瘍抑制機序とバイオマーカー解析 (研究課題/領域番号: 21K15488 )
線維細胞を用いた血管新生阻害薬の薬剤耐性及び安全性に関わるバイオマーカー開発 (研究課題/領域番号: 20K08542 )
免疫チェックポイント阻害薬および血管新生阻害薬併用療法における線維細胞の機能解析 (研究課題/領域番号: 19K16746 )
肺がん・中皮腫に対する新規複合がん免疫療法の免疫学的基盤確立から臨床への展開 (研究課題/領域番号: 19H03668 )
研究者番号（00833732）による検索

特任講師 : 三橋惇志

研究活動

個人のホームページ

専門分野

研究テーマ

著書・論文

学術論文(審査論文):

総説・解説:

国際会議:

国内講演発表:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

特任講師 : 三橋 惇志

研究活動

個人のホームページ

専門分野

研究テーマ

著書・論文

学術論文(審査論文):

総説・解説:

国際会議:

国内講演発表:

科学研究費補助金 (KAKEN Grants Database @ NII.ac.jp)

特任講師 : 三橋惇志